CYBN
Cybin Inc

7,436
Loading...
Loading...
Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
50

Frequently Asked Questions

What is Market Cap of Cybin Inc?
What is the 52-week high for Cybin Inc?
What is the 52-week low for Cybin Inc?
What is Cybin Inc stock price today?
What was Cybin Inc stock price yesterday?
What is the PE ratio of Cybin Inc?
What is the Price-to-Book ratio of Cybin Inc?
What is the 50-day moving average of Cybin Inc?
How many employess does Cybin Inc has?

Latest CYBN News

View

Advertisement. Remove ads.

Advertisement. Remove ads.